Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Practice Patterns in Management of Polycythemia Vera

J Natl Compr Canc Netw; 2016 Oct 14; Kander, et al

Publish date:: November 18, 2016

There is variability in diagnosis and treatment approaches of polycythemia vera (PV) even in light of WHO guidelines and the advances in JAK2 therapy, according to a survey of 71 hematologists.

Investigators surveyed clinicians about their diagnostic and treatment approaches of PV in the post-JAK2 V617F era. Among the results:

Diagnostic testing varied depending on clinical experience and practice type.
There were marked differences in target hematocrit and platelet count.

The authors concluded that US-based guidelines for myeloproliferative neoplasms are needed to create disease management consistency.

Citation:

Kander E, Moliterno A, Rademaker A, Streiff M, Spivak J, Stein B. Practice patterns in the diagnosis and treatment of polycythemia vera in the post-JAK2 V617F discovery era. J Natl Compr Canc Netw. 2016;14(10):1238-1245.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Hematologic Malignancies

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10

Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al

These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al

Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al

The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al